Company news

GT Biopharma, Inc. news in 2021

GT Biopharma, Inc.'s news releases, calls and decks from 2021, newest first.

View company

GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 9, 2021

GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey

November 7, 2021

GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021

September 14, 2021

GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies

September 12, 2021

GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies

September 8, 2021

GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer

August 22, 2021

GT Biopharma Provides Second Quarter 2021 Business Update

August 12, 2021

GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results

August 5, 2021

GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™

August 2, 2021

GT Biopharma Announces $16 million in Warrant Exercise Proceeds

July 27, 2021

GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota

July 6, 2021

GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference

June 22, 2021

GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4: 00 PM ET

May 17, 2021

GT Biopharma Reports First Quarter 2021 Results

May 16, 2021

GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates

May 11, 2021

GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S. Miller, M.D. to Consulting Chief Scientific Officer

April 25, 2021

GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update

April 18, 2021

GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients

April 11, 2021

GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial

April 7, 2021

GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results

March 16, 2021

GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer

March 7, 2021

GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment

March 3, 2021

GT Biopharma Transfers TriKE™ Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid Tumor Clinical Trials

February 17, 2021

GT Biopharma Announces Closing of $23.7 Million Public Offering

February 15, 2021

GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market

February 10, 2021

GT Biopharma Appoints Two New Independent Directors

January 18, 2021

GT Biopharma Announces Eighth Patient Begins Treatment Of GTB-3550

January 11, 2021

GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call

January 3, 2021

Calls in 2021

Decks in 2021